Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de fase III de HMPL-760 en combinación con R-GemOx frente a placebo en combinación con R-GemOx en DLBCL recidivante/refractario

9 de noviembre de 2026 actualizado por: Hutchmed

Un Estudio Aleatorizado de Fase III, Doble Ciego, Controlado Positivo para Evaluar la Eficacia, Seguridad y Farmacocinética de HMPL-760 en Combinación con R-GemOx Frente a Placebo en Combinación con R-GemOx en Pacientes con Linfoma Difuso de Células B Grandes (DLBCL) Recaído/Refractario

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Descripción general del estudio

Descripción detallada

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

240

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Baoding, Porcelana
        • Reclutamiento
        • Baoding NO.1 Central Hospital
        • Contacto:
        • Investigador principal:
          • Haiying Yao
      • Beijing, Porcelana
        • Reclutamiento
        • Beijing GoBroad Hospital
        • Investigador principal:
          • Kai Hu
        • Contacto:
      • Beijing, Porcelana
        • Reclutamiento
        • BEIJING TONGREN HOSPITAL, Capital Medical University
        • Investigador principal:
          • Liang Wang
        • Contacto:
      • Bengbu, Porcelana
        • Reclutamiento
        • The First Affiliated Hospital of Bengbu Medical College
        • Contacto:
        • Investigador principal:
          • Yanli Yang
      • Changchun, Porcelana
        • Reclutamiento
        • The First Hospital of Jilin University
        • Investigador principal:
          • Ou Bai
        • Contacto:
          • Ou Bai
          • Número de teléfono: 13039046656
          • Correo electrónico: lbl2054@163.com
      • Changsha, Porcelana
        • Reclutamiento
        • Hunan Cancer Hospital
        • Investigador principal:
          • Hui Zhou
        • Contacto:
      • Changsha, Porcelana
        • Reclutamiento
        • The Second Xiangya Hospital of Central South University
        • Investigador principal:
          • Hongling Peng
        • Contacto:
      • Changsha, Porcelana
        • Reclutamiento
        • People's Hospital of Hunan Province
        • Contacto:
          • Can Liu
          • Número de teléfono: 137 8728 5260
          • Correo electrónico: 617170469@qq.com
        • Investigador principal:
          • Can Liu
      • Chengdu, Porcelana
        • Reclutamiento
        • West China Hospital of Sichuan University
        • Investigador principal:
          • Liqun Zou
        • Contacto:
      • Chengdu, Porcelana
        • Reclutamiento
        • Sichuan Provincial People's Hospital
        • Contacto:
          • Xiaobing Huang
          • Número de teléfono: 18981838236
          • Correo electrónico: hxb_trial@163.com
        • Investigador principal:
          • Xiaobing Huang
      • Chongqing, Porcelana
        • Reclutamiento
        • The First Affiliated Hospital of Chongqing Medical University
        • Investigador principal:
          • Xin Wang
        • Contacto:
      • Chongqing, Porcelana
        • Reclutamiento
        • Chongqing University Cancer Hospital
        • Investigador principal:
          • Yao Liu
        • Contacto:
      • Fujian, Porcelana
        • Reclutamiento
        • Quanzhou First Hospital.Fujian
        • Contacto:
        • Investigador principal:
          • Xiongpeng Zhu
      • Fuzhou, Porcelana
        • Reclutamiento
        • Fujian Medical University Union Hospital
        • Investigador principal:
          • Jianzhen Shen
        • Contacto:
          • Jianzhen Shen
          • Número de teléfono: 138 0955 2722
          • Correo electrónico: doctorsjz@163.com
      • Guangzhou, Porcelana
        • Reclutamiento
        • Sun Yat-sen University Cancer Center
        • Investigador principal:
          • Zhiming Li
        • Contacto:
          • Zhiming Li
          • Número de teléfono: 13719189172
          • Correo electrónico: lzmsysu@163.com
      • Guangzhou, Porcelana
        • Reclutamiento
        • Guangdong Provincial People's Hospital
        • Contacto:
          • Xiaojuan Wei
          • Número de teléfono: 86 13560097145
          • Correo electrónico: jxw919@hotmail.com
        • Investigador principal:
          • Xiaojuan Wei
      • Guangzhou, Porcelana
        • Reclutamiento
        • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
        • Investigador principal:
          • Yuhua Li
        • Contacto:
      • Guiyang, Porcelana
        • Reclutamiento
        • The Affiliated Hospital of Guizhou Medical University
        • Investigador principal:
          • Yan Zhang
        • Contacto:
      • Hangzhou, Porcelana
        • Reclutamiento
        • Zhejiang Cancer Hospital
        • Investigador principal:
          • Haiyan Yang
        • Contacto:
      • Hangzhou, Porcelana
        • Reclutamiento
        • The First Affiliated Hospital, Zhejiang University
        • Investigador principal:
          • Zhen Cai
        • Contacto:
      • Harbin, Porcelana
        • Reclutamiento
        • Harbin Medical University Cancer Hospital
        • Contacto:
          • Qingyuan Zhang
          • Número de teléfono: 13313612989
          • Correo electrónico: sy86298276@163.com
        • Investigador principal:
          • Qingyuan Zhang
      • Hefei, Porcelana
        • Reclutamiento
        • The Second Affiliated Hospital of Anhui Medical University
        • Contacto:
          • Zhimin Zhai
          • Número de teléfono: 13855147434
          • Correo electrónico: zzzm889@163.com
        • Investigador principal:
          • Zhimin Zhai
      • Jinan, Porcelana
        • Reclutamiento
        • Qilu Hospital of Shandong University
        • Contacto:
        • Investigador principal:
          • Shuqian Xu
      • Jinan, Porcelana
        • Reclutamiento
        • Shandong Cancer Hospital & Institute
        • Investigador principal:
          • Zengjun Li
        • Contacto:
          • Zengjun Li
          • Número de teléfono: 15735178591
          • Correo electrónico: zengjunli@163.com
      • Kunming, Porcelana
        • Aún no reclutando
        • The First Affiliated Hospital of Kunming Medical University
        • Contacto:
        • Investigador principal:
          • Mingxia Shi
      • Nanchang, Porcelana
        • Reclutamiento
        • Jiangxi Cancer Hospital
        • Investigador principal:
          • Yan Huang
        • Contacto:
      • Nanjing, Porcelana
        • Reclutamiento
        • Jiangsu Cancer Hospital
        • Investigador principal:
          • Yan Zhang
        • Contacto:
      • Nanjing, Porcelana
        • Reclutamiento
        • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
        • Contacto:
          • Jingyan Xu
          • Número de teléfono: 86 13951969610
          • Correo electrónico: xjy1967@sina.com
        • Investigador principal:
          • Jingyan Xu
      • Nanning, Porcelana
        • Reclutamiento
        • The First Affiliated Hospital of Guangxi Medical University
        • Investigador principal:
          • Zhigang Peng
        • Contacto:
      • Qingdao, Porcelana
        • Reclutamiento
        • The Affiliated Hospital of Qingdao University
        • Contacto:
        • Investigador principal:
          • Xia Zhao
      • Shanghai, Porcelana
        • Reclutamiento
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Investigador principal:
          • Weili Zhao
        • Contacto:
          • Weili Zhao
          • Número de teléfono: 86 13512112076
          • Correo electrónico: zwl_trial@163.com
      • Shanghai, Porcelana
        • Reclutamiento
        • Tongji Hospital of Tongji University
        • Contacto:
        • Investigador principal:
          • Ping Li
      • Shanghai, Porcelana
        • Aún no reclutando
        • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
        • Investigador principal:
          • Ligen Liu
        • Contacto:
      • Shenyang, Porcelana
        • Reclutamiento
        • Shengjing Hospital of China Medical University
        • Investigador principal:
          • Wei Yang
        • Contacto:
          • Wei Yang
          • Número de teléfono: 18940251012
          • Correo electrónico: sjyangw@163.com
      • Shenzhen, Porcelana
        • Reclutamiento
        • Shenzhen people's hospital
        • Investigador principal:
          • Jihao Zhou
        • Contacto:
      • Taiyuan, Porcelana
        • Reclutamiento
        • Shanxi Provincial Cancer Hospital
        • Investigador principal:
          • Liping Su
        • Contacto:
      • Tangshan, Porcelana
        • Reclutamiento
        • North China University of Science and Technology Affiliated Hospital
        • Contacto:
          • Zhenyu Yan
          • Número de teléfono: 15931508262
          • Correo electrónico: hbyzy2011@163.com
        • Investigador principal:
          • Zhenyu Yan
      • Tianjin, Porcelana
        • Reclutamiento
        • Tianjin Medical University Cancer Institute & Hospital
        • Investigador principal:
          • Zhengzi Qian
        • Contacto:
          • Zhengzi Qian
          • Número de teléfono: 13702031222
          • Correo electrónico: qzz@163.com
      • Tianjin, Porcelana
        • Reclutamiento
        • Tianjin People's Hospital
        • Contacto:
        • Investigador principal:
          • Xingli Zhao
      • Tianjin, Porcelana
        • Reclutamiento
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • Investigador principal:
          • Dehui Zou
        • Contacto:
      • Wenzhou, Porcelana
        • Reclutamiento
        • The First Affiliated Hospital of WMU
        • Contacto:
          • Songfu Jiang
          • Número de teléfono: 86 15305770033
          • Correo electrónico: jiangsongfu@189.cn
        • Investigador principal:
          • Songfu Jiang
      • Wuhan, Porcelana
        • Reclutamiento
        • Hubei Cancer Hospital
        • Investigador principal:
          • Huijing Wu
        • Contacto:
      • Wuhan, Porcelana
        • Reclutamiento
        • Wuhan Union Hospital of China
        • Investigador principal:
          • Liling Zhang
        • Contacto:
          • Liling Zhang
          • Número de teléfono: 15871725926
          • Correo electrónico: lily1228@sina.com
      • Xi'an, Porcelana
        • Reclutamiento
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Investigador principal:
          • Pengcheng He
        • Contacto:
          • Pengcheng He
          • Número de teléfono: 18991232609
          • Correo electrónico: hepc_gcp@163.com
      • Xi'an, Porcelana
        • Reclutamiento
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • Investigador principal:
          • Jie Liu
        • Contacto:
          • Jie Liu
          • Número de teléfono: 86 18092662371
          • Correo electrónico: lieujie@163.com
      • Xiamen, Porcelana
        • Aún no reclutando
        • The First Affiliated Hospital of Xiamen University
        • Investigador principal:
          • Bing Xu
        • Contacto:
      • Xuzhou, Porcelana
        • Reclutamiento
        • The Affiliated Hospital of Xuzhou Medical University
        • Contacto:
        • Investigador principal:
          • Wei Sang
      • Zhengzhou, Porcelana
        • Reclutamiento
        • Henan Cancer Hospital
        • Investigador principal:
          • Keshu Zhou
        • Contacto:
      • Zhengzhou, Porcelana
        • Reclutamiento
        • The First Affiliated Hospital of Zhengzhou University
        • Contacto:
          • Xudong Zhang
          • Número de teléfono: 13633825183
          • Correo electrónico: feverxxd@126.com
        • Investigador principal:
          • Xudong Zhang
      • Ürümqi, Porcelana
        • Reclutamiento
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Investigador principal:
          • Yan Li
        • Contacto:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana
        • Reclutamiento
        • Fudan University Shanghai Cancer Center
        • Contacto:
          • Fangfang Lv
          • Número de teléfono: 18017312613
          • Correo electrónico: Lvff80@163.com
        • Investigador principal:
          • Fangfang Lv

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: The experimental group

Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Patients will receive HMPL-760 once daily (QD) orally.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Otros nombres:
  • Clorhidrato de gemcitabina para inyección
  • Inyección de rituximab
  • Inyección de oxaliplatino
Comparador de placebos: The control group

Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Otros nombres:
  • Clorhidrato de gemcitabina para inyección
  • Inyección de rituximab
  • Inyección de oxaliplatino

Patients will receive HMPL-760 placebo once daily (QD) orally.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression-free survival (PFS)
Periodo de tiempo: Up to approximately two years

Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

Up to approximately two years
End of treatment (EOT)
Periodo de tiempo: Up to approximately two years

Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

Up to approximately two years
Systemic antitumor therapy
Periodo de tiempo: Up to approximately two years

Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

Up to approximately two years
Overall survival (OS)
Periodo de tiempo: Up to approximately two years

OS is defined as the time from randomization to death due to any cause.

Up to approximately two years
systematic anti-tumor therapy
Periodo de tiempo: Up to approximately two years

OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

Up to approximately two years
Premature withdrawal from study treatment
Periodo de tiempo: Up to approximately two years

OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

Up to approximately two years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Independent review committee (IRC)-assessed PFS
Periodo de tiempo: Up to approximately two years

Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
Periodo de tiempo: Up to approximately two years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
Periodo de tiempo: Up to approximately two years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
Periodo de tiempo: Up to approximately two years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
Periodo de tiempo: Up to approximately two years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
Periodo de tiempo: Up to approximately two years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

Up to approximately two years
Safety Endpoints
Periodo de tiempo: Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Periodo de tiempo: At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

At the end of Cycle 4 (each cycle is 21 days)]

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Biomarker assessment
Periodo de tiempo: Up to approximately two years

Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Periodo de tiempo: Up to approximately two years

Human metabolites of HMPL-760 when co-administered with R-GemOx

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Periodo de tiempo: Up to approximately two years

maximum concentration in steady-state (Cmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Periodo de tiempo: Up to approximately two years

time to maximum concentration in steady-state (Tmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Periodo de tiempo: Up to approximately two years

Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Periodo de tiempo: Up to approximately two years

The rate at which the drug is eliminated from the body (CL/F) (if applicable )

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Periodo de tiempo: Up to approximately two years

The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

Up to approximately two years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Weili Zhao, Ruijin Hospital

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de marzo de 2026

Finalización primaria (Estimado)

30 de abril de 2028

Finalización del estudio (Estimado)

30 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

28 de enero de 2026

Primero enviado que cumplió con los criterios de control de calidad

6 de febrero de 2026

Publicado por primera vez (Actual)

13 de febrero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir